

In re application of Evans et al.
Application No.: 10/627,160
Page 2 of 15

Atty. Dkt. No. SALK1920-2
(088802-4108)

Amendments to the Claims/Listing of Claims

Please amend claims 1-3, 19 and 20 and cancel claims 5-11 and 14-18 without prejudice.
This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A method for ~~modulating~~ inhibiting or reducing growth of ~~neoplastic myelogenous leukemia~~ cells, wherein said growth is mediated by peroxisome proliferator activated receptor- γ (PPAR- γ), said method comprising contacting said cells with a composition effective to ~~modulate~~ inhibit or reduce said growth,

wherein said composition comprises:

at least one PPAR- γ -selective activator, and


at least one retinoid X receptor (RXR) selective agonist,

in a pharmaceutically acceptable carrier therefore,

wherein said PPAR- γ -selective activator is a PPAR- γ -selective prostaglandin; and

wherein said retinoid X receptor (RXR) selective agonist is a substituted benzoic acid, a substituted nicotinic acid or a substituted carboxylated furan.

2. (Currently amended) A method according to claim 1 wherein said ~~PPAR- γ activator is a~~ PPAR- γ -selective prostaglandin has structure II as follows: or prostaglandin-like compound or precursor thereof



DLMR_273873.7

In re application of Evans et al.
Application No.: 10/627,160
Page 3 of 15

Atty. Dkt. No. SALK1920-2
(088802-4108)

wherein:

A is selected from hydrogen or a leaving group at the α - or β - position of the ring, or A is absent when there is a double bond between C^{α} and C^{β} of the ring;

X is an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl group having in the range of 2 up to 15 carbon atoms; and

Q is an alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl or substituted alkynyl group having in the range of 2 up to 15 carbon atoms.

3. (Currently amended) A method according to claim 2 wherein said PPAR- γ -selective prostaglandin is a prostaglandin-J₂, or a prostaglandin-D₂, or a precursor thereof.

4. (Original) A method according to claim 3 wherein said prostaglandin-J₂ is prostaglandin-J₂, 12-prostaglandin-J₂ or 15-deoxy-12,14-prostaglandin-J₂.

5-11. (Cancelled)

12. (Original) A method according to claim 1 wherein said retinoid X receptor (RXR) selective agonist is 6-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]nicotinic acid (LG268).

13. (Original) A method according to claim 1 wherein said retinoid X receptor (RXR) selective agonist is 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid.

14-18. (Cancelled)

DLMR_273873.7

In re application of Evans et al.
Application No.: 10/627,160
Page 4 of 15

Atty. Dkt. No. SALK1920-2
(088802-4108)

19. (Currently amended) A method for treating a subject suffering from ~~a disease~~ state myelogenous leukemia which is the result of neoplastic cell proliferation of myelogenous leukemia cells which express PPAR- γ , said method comprising administering to said subject an amount of a therapeutic composition effective to ameliorate the effect of neoplastic cell proliferation on said cells,

wherein said therapeutic composition comprises:

at least one PPAR- γ -selective activator, and

at least one retinoid X receptor (RXR) selective agonist,

in a pharmaceutically acceptable carrier therefore;

wherein said PPAR- γ -selective activator is a PPAR- γ -selective prostaglandin; and

wherein said retinoid X receptor (RXR) selective agonist is a substituted benzoic acid, a substituted nicotinic acid or a substituted carboxylated furan.

20. (Currently amended) A composition comprising at least one PPAR- γ -selective activator and at least one retinoid X receptor (RXR) selective agonist;

wherein said PPAR- γ -selective activator is a PPAR- γ -selective prostaglandin; and

wherein said retinoid X receptor (RXR) selective agonist is a substituted benzoic, a substituted nicotinic acid or a substituted carboxylated furan.

DLMR_273873.7